REVIEW ARTICLE

Resolving Solubility Problems and Providing an Overview of Excipients to Boost Oral Drug Bioavailability

Mujibullah Sheikh[1], Mohammad Tauqeer[2], Gaurav Mude[1], Surbhi Bhope[2], Tarannum Sayyad[3], Sandip Chaudhari[3], Prashant Nikumbh[3]

[1]Department of Pharmacology, Datta Meghe College of Pharmacy DMIHER (Deemed to be University), Wardha, Maharashtra, India, [2]Department of Pharmacognosy, K. C. Bajaj College of Pharmacy and Research, Nagpur, Maharashtra, India, [3]Department of Pharmaceutics, Shri. Prakashchand Jain College of Pharmacy and Research, Palaskehede, Maharashtra, India

Abstract

In this study, the methods and resources to improve the bioavailability and solubility of poorly soluble medications are covered. Common supports that may function as solubilizers, disintegrants, and binders in tablet formulations include hydroxypropyl cellulose (HPC) and starch. It has been shown that HPC increases the solubility and rate of drug dissolution for medications such as caffeine and itraconazole. HPC is soluble in water and polar organic solvents. When combined with other components, it may be used as a binder, solvent, or partly preformed corn starch to assist in making poorly soluble medications more soluble and bioavailable. In most countries, the use of Starch 1500 and microcrystalline cellulose has led to commercial success in new automotive generic and over-the-counter market categories. Decreased reliability offer moisture action, which is crucial for coatings and packing films. The study states that these procedures and the use of excipients may be useful means of resolving solubility issues and enhancing oral medication bioavailability.

Key words: Bioavailability, drug formulation, excipients, resolving solubility, solubility

INTRODUCTION

Oral delivery is the most often used and practical approach for administering drugs. However, since they are inorganic and not very soluble, oral drugs often have little effect. Among the primary challenges in drug development is determining the drug's solubility, which is a crucial factor in determining the pace and amount of drug absorption. Improving drug bioavailability and solubility is a crucial stage in the drug-making process since low solubility may result in poor bioavailability, which can lead to poor clinical results, large dosages, and high costs. Ingredients known as excipients are added to pharmaceutical formulations to enhance their biological, physical, and stability characteristics. Excipients may increase permeability, inhibit corrosion, and promote medication miscibility and dispersion. Sponsors have the power to modify how medications are released, regulate flavor and texture, and make administration easier. Excipients are thus crucial to the creation and production of drugs.

This review article's goal is to provide methods and resources for enhancing the efficiency and bioavailability of oral medications. The physicochemical characteristics of pharmaceuticals that impact their bioavailability and solubility, medication administration methods for absorption and reduction, and variables influencing excipient effectiveness will all be covered in this article. The study will also address a wide range of adjuvants that are often found in oral medications, such as metabolites, polymers, cyclodextrins, and lipid-based adjuvants.

Address for correspondence:
Gaurav Mude, Datta Meghe College of Pharmacy DMIHER (Deemed to be University), Wardha - 442 001, Maharashtra, India. Phone: +91-8007095656.
E-mail: gaurav.pharmacy@dmiher.edu.in

Received: 04-11-2023
Revised: 21-12-2023
Accepted: 30-12-2023

PHYSICOCHEMICAL CHARACTERISTICS OF DRUG INFLUENCE ABSORPTION AND SOLUBILITY

Molecular weight

A drug's physicochemical characteristics are crucial in determining its solubility and bioavailability. Solubility is the capacity of a medication to dissolve in a solvent. While the proportion percent a dosage that enters the bloodstream is referred to as bioavailability. After being delivered, the molecular weight and physicochemical characteristics of pharmaceuticals are significant factors in establishing their solubility and bioavailability. Measuring pharmacological activity requires aqueous solubility, and precise activity measurements can only be achieved when the material is highly soluble.[1] A medication's water solubility and bioavailability make up around 40% of its waste throughout the drug development process.[2] The medication's solubility significantly affects absorption, pharmacokinetics, and the route of drug administration.[1]

At least in part, molecular properties that impact two drug candidate oral bioavailability physicochemical parameters water solubility and lipophilicity significantly affect the effectiveness of molecular weight as a predictor of oral bioavailability.[3] While sophisticated medications created by new technology tend to have higher molecular weights and lipophilicity due to bioavailability, increased lipophilicity is linked to unfavorable side effects.[4]

Lipophilicity

Drug permeability across lipid cell membranes and drug interactions with target proteins are both influenced by lipophilicity.[5] It is crucial to take lipophilicity into account when creating novel formulations since it is related to pharmacology and pharmacokinetics and has shown a noteworthy influence on the absorption, distribution, metabolic processes, elimination, and toxicity characteristics of drugs.[6] In the last 15 years, a significant amount of research has been done on the impact of lipophilicity on drug manufacturing and discovery. Their primary focus is on the ideal location of the lipid droplets and how the monitoring of lipid metabolism indicators can significantly contribute to the overall quality of drug candidates in pathways using the various methods. There is growing evidence that controlling physicochemical properties like lipophilicity within a defined optimum range can improve drug quality and the chances of clinical success. However, it still depends on continuing to rely on new systems with increased intensity. Furthermore, without attention to maintaining optimal body chemistry.[5]

PKa

A compound's pKa indicates its ionization state at various pH levels. Medications with pKa values around the pH of the stomach are highly soluble and recoverable because they probably have non-ionized forms that diffuse quickly into biological tissues.[3] An uncharged drug molecule (lipophilic) will diffuse across cell membranes more quickly than a drug molecule that is charged (hydrophilic), according to pH-distribution theory calculations.[7]

Crystal

A drug's crystal structure is comprised of all other physical and chemical characteristics that may impact its solubility and absorption. The association of molecules in a solid state, which might impact the physical and chemical properties of the medicinal substance, is referenced by the crystal form.[8] The effectiveness of a dose shape may depend on the crystal structure, especially for substances that naturally impede drug delivery.[9] Pharmaceutical drug manufacture and storage may result in changes to a drug's crystal structure, which can impact the medication's solubility, dissolution profile, and bioavailability.[10] Therefore, while creating new medications, it's essential to keep in mind the drug's crystal form. It is possible to alter a drug's crystalline structure and enhance its physical characteristics with the use of glass mechanical procedures. For instance, using a crystal mechanical method to alter the crystalline route of the respiratory medication theophylline enhanced its water dissociation.[11]

Hydrogen bonding

Another physicochemical characteristic that may influence the solubility and absorption of drugs is hydrogen bonding. One kind of intermolecular interaction that happens between hydrogen atoms and electronegative atoms like oxygen, nitrogen, and fluorine is called hydrogen bonding. The solubility, melting point, and water formation of organic compounds are all influenced by hydrogen bonding. Hydrogen bonding in pharmaceutical formulations may impact medication bioavailability, absorption, and permeability.[12] For instance, drug solubility in water may be increased via hydrogen bonding between the drug and water molecules, which can enhance the medication's bioavailability.[13]

Particle size

Another biological component that may influence the solubility and adsorption of drugs is particle size. Pharmaceutical materials' active ingredient and excipient particle distribution are crucial physical characteristics. Particle size, distribution, and shape can impact the size, complexity, processability, and chemical makeup of pharmaceutical products. Particle size and material composition are known to be correlated with the dispersion, absorption, and homogeneity of the material. Particle reduction by hydrolysis may aid in the creation of novel compounds.

Considerable research has been done on the effect of particle length on pharmaceutical dissolving fees. Reducing the length of particles is a useful strategy for increasing the dissolving rate of hydrophobic medications.[14] The current study aimed to investigate whether the length of the drug particle affects the physicochemical properties, dissolving behaviors, and complexation of the drug or cyclodextrins. The results verified that decreasing the particle size might boost the interactions between the medication and β-CD. In addition, there was a six-fold increase in solubility when ibuprofen was evaluated alone in water. Particle length is thus a crucial physicochemical component that may affect the solubility and absorption of medication.[14]

Solubility based on United States pharmaceuticals

The soluble nature of a chemical is described by the USP as its solubility, and the rate at which it achieves the limit of solubility is the equilibrium solubility at the thermodynamic equilibrium limit in Incomplete. Because of the solution, apparent solubility may differ from equilibrium solubility in any direction. Concentration units such as molality, weight/volume, weight/ratio, molarity, and mole fraction. The term "weight" might be employed to indicate solubility.[15] Typically, the USP uses broader terminology to define solubility, such as partly soluble, somewhat soluble, intractable, highly soluble, soluble, and soluble. Water solubility metrics are also used by the USP for different substances. The molecular mixture of two pure substances in thermodynamic balance is measured by a substance's solubility in another. The ratio of a given solvent to a defined solution, or saturated solution composition, indicates the thermodynamic restrictions on this solubility. To get precise and trustworthy results on a substance's solubility, it is essential to regulate these parameters during solubility measurements. The USP Pharmacopoeia utilizes seven different ways to communicate solubility to define "solubility" in general, as Table 1 illustrates.

The solubility of drugs is a major factor in the creation of novel medications. Solubility is the molecular weight of a combination of two unadulterated substances in thermodynamic balance, according to the USP. The qualities of saturation, defined as the ratio of the given volume to the specified volume, serve as a representation of the temperature limit of solubility. The volume of water in a quantity, such as weight/volume, molality, mole fraction, or mole ratio, may be used to indicate soluble matter.[15] Important elements influencing a substance's equilibrium solubility include its solvent characteristics and the influence of test conditions. To achieve standard values that are accurate and dependable indicators of a substance's equilibrium solubility, these factors must be continuously monitored throughout the solubility measurement procedure.Pharmaceutical companies must take water solubility into account while creating new formulations.[16] A compound's pharmacokinetics and bioactivity are significantly influenced by its water solubility. A chemical-water link is broken during chemical dispersion, creating a new bond between the two substances.[17] The strength of these interactions determines how soluble the medication is. An approach to biopharmaceutical classification (BCS) product's water solubility is one of its essential features.[18] Figure 1 represents the biopharmaceuticals classification scheme.[19] Chemical solubility is measured by multiplying the amount of solution needed to dissolve one gram of solution at a given temperature by the maximum amount of a substance that can be completely dissolved in that solution at that temperature and pressure level. The criteria for an insoluble or insoluble solvent need almost none over 10,000 parts, in contrast to those for a highly soluble solvent, which requires less than one part soluble to dissolve one gram.

METHODS FOR CREATING AND DELIVERING MEDICATIONS THAT HAVE LOW WATER SOLUBILITY

Water-soluble compounds provide several important issues for the pharmaceutical sector. Drugs with low solubility may have ineffective drug delivery and low bioavailability. Particle reduction, nanosuspension, surfactant application, salt creation, dispersion, amorphous formulation, lipid formulation, and co-solvent regimes are a few techniques to improve drug waste, however.[16] The drug's physicochemical characteristics and the preferred administration method influence the route selection. Taken into account, In conclusion, the initiative combines science and art with

Table 1: Solubility based on USP

Definition of solubility in terms of description	Proportions of the solvent needed for each solute component	Solubility range (mg/mL)	Solubility assigned (mg/mL)
Superior soluble	<1	>1000	1000
Being readily soluble	From 1–10	100–1000	100
Soluble	From 10–30	33–100	33
Not very soluble	From 30–100	10–33	10
Moderately soluble	From 100–1000	1–10	1
Very little solubility	From 1000–10000	0.1–1	0.1
Technically insoluble	>10.000	<0.1	0.01

pharmaceuticals to create and administer water-soluble medications that guarantee bioavailability and steady therapeutic efficacy using a range of methods.[17]

Figure 2 illustrates three categories of pharmaceutical strategies: chemical, physical, and delivery methods, which are categorized according to the kind of change linked to poor drug solubility. Naturally, these techniques may be used alone or in combination.



Figure 1: The biopharmaceuticals classification scheme

CHEMICAL ALTERATIONS

PH correction

Pharmaceutical formulations may thus be made more soluble and dissolve more quickly by altering their pH, which will increase their bioavailability. For instance, to increase their soluble nature and bioavailability in the alkaline environment of the small intestine, acidic substances may be prepared as salts containing significant counterions.[8]

Other methods may be used in addition to pH modification to increase the bioavailability of oral medications that are poorly soluble. These techniques consist of solid dispersion, lipid formation, co-crystal creation, and nanosuspension.[18]

PRO-DRUG DESIGN

One useful approach for resolving solubility problems in drug development is pre-drug design. One of the primary difficulties in medication development is insolubility; nevertheless, pretreatment may help poorly soluble medicines become more soluble and disperse.[19] Pharmaceutical agents are chemical substances that, via enzymatic or chemical processes, are transformed from inactive to bioactive forms.[20] Adding a medication to



Figure 2: A graphic representation of the many methods for creating and delivering drugs that aren't very soluble in water

a lipid moiety may enhance its lipid profile and boost its water poorly soluble medication solubility and bioavailability. Pro-drug design may also be used to enhance a drug's pharmacokinetic characteristics, including toxicity, permeability, and stability.

PHYSICAL MODIFICATIONS

Alternate solid-state one technique for enhancing the solubility and bioavailability of drugs that have low water solubility is physical modification. To increase the material's drug solubility, its physical state is changed. A compound may, for instance, go from glassy to amorphous, increasing its surface area and accelerating its breakdown. One useful approach for resolving solubility problems in pharmaceutical formulations is physical change.[8]

Particle size reduction, co-crystal formation, amorphous formulation, lipid formulation, and solid dispersion are among the alterations that may be made. Happens. To produce co-crystals, a crystal complex between the drug and its co-crystal form must develop. This process may increase the medication's solubility and dispersion. The medicine is synthesized in an amorphous state to improve its better form of solubility and dissolution in amorphous formulations. Drugs must be synthesized in lipid-based systems to benefit from lipid synthesis, which may increase a drug's bioavailability and solubility.[20]

SMALL DRUG PARTICLES

To solve solubility problems in pharmaceutical formulations, microparticles are crucial. Oral bioavailability, dispersion, and solubility may all be impacted by particle size. Due to its high concentration on the surface, particulate matter may dissolve more quickly and become more soluble.[21] For instance, as compared to bulk medications, coenzyme Q10 nanocrystals with diameters <200 nm demonstrated noticeably higher solubility, dissolving rate, and oral bioavailability.[22] Poorly soluble medications may enhance their bioavailability and solubility via particle reduction and other physical changes. To produce co-crystals, a crystal complex between the drug and its co-crystal form must develop.[23] This process may increase the medication's solubility and dispersion. The medicine is synthesized in an amorphous state to improve its better form of solubility and dissolution in amorphous formulations.[24] Drugs must be synthesized in lipid-based systems to benefit from lipid synthesis, which may increase a drug's bioavailability and solubility. The medication is spread in a dense matrix during dispersion, which may enhance the drug's wear and dispersion characteristics. Drugs with low solubility may be given better dissolution and bioavailability by using these metabolic changes alone or in combination.[25]

CO-SOLVENTS

Adjuvants called co-solvents are used to enhance the solubility and bioavailability of poorly soluble medicines. A combination of two or more substances that dissolve a medication and make it more wearable is called a co-solvent. The solubility of pharmaceuticals in constant volume mixed solvent liquid-based vehicles, particularly low-water-soluble medications, is a limitation on the development of co-solvent formulations.[26] Oral medications may have their bioavailability increased by adding additional adjuvants and co-solvents. Adjuvants may increase the solubility and bioavailability of poorly soluble medications. Examples of these include co-crystal formers, lipid formulations, solid dispersions, and nanosuspensions.[27] A soluble and quick dispersion is produced when the number of drug particles in the nanosuspension is decreased. Physical modifications such as solid dispersion, amorphous formulation, co-crystal formation, particle reduction, and lipid formulation may also improve the solubility and bioavailability of poorly soluble pharmaceuticals.

LIPIDS AND SURFACTANTS INCREASE

Lipids and surfactants are examples of excipients that may be used to improve the solubility and bioavailability of poorly soluble medications. Enhancing the miscibility and dispersibility of capsules by including surfactants and/or lipid-based excipients Low-water-solubility medications may be better delivered using lipid-based oral preparations. Fatty matrix Accelerated wetting may enhance the absorption of medication particles that are insoluble in water.[28] Additionally, co-solvents may be used with lubricants and surfactants to increase the solubility and bioavailability of poorly soluble medications. It is acknowledged that using lipid surfactant formulations may increase the bioavailability of poorly soluble medications.[29] A medicine must be synthesized in a lipid-based system to undergo lipid synthesis, which may increase the drug's solubility and bioavailability.[30]

Adjuvants such as surfactants and lipids may effectively boost the solubility and bioavailability of poorly soluble medicines. Physical changes that increase the solubility and bioavailability of poorly soluble pharmaceuticals include drug size reduction, cocrystal formation, amorphous formulation, lipid formulation, and solid dispersion. The physicochemical characteristics of the medication and the preferred mode of delivery will determine the technique of choice. Predicting prenatal physiological outcomes and ensuring consistent bioavailability are important aspects of pharmaceutical formulations.

As shown in Figure 3, some of the surfactants adsorb to the system's liquid-air or liquid-liquid interfaces, reducing and stabilizing interfacial tension. Emulsions may be stabilized by using this function. Drugs, aqueous parenteral solutions, nasal sprays, and eye drop solutions may all use



Figure 3: Surfactant distribution and the capacity to form structures via self-assembly in an aqueous medium: (a) micelles, (b) liposomes, and (c) emulsion droplets



Figure 4: The hydroxypropyl



Figure 5: The chemical structure of copovidone



Figure 6: Hydroxypropyl cellulose

cyclodextrins.[31] There are now at least six different types of cyclodextrins on the market. To boost the aqueous solubility of energetic materials that are weakly soluble in water and enhance stability, cyclodextrins have mostly been utilized as complexing dealers.[32] Poorly soluble drugs may become more soluble and more bioavailable by using cyclodextrins as excipients. By adding complexes to medications,



Figure 7: Starch

cyclodextrins may improve the solubility and solubility of the medications. In addition, cyclodextrins may increase the solubility of pharmaceuticals in high solubility, highly soluble, sparingly soluble, and co-solvents; in contrast, poorly soluble medications are biologically soluble.may be enhanced to increase accessibility as well.[33]

ADMINISTRATION MODIFICATION

Two types of adjuvants may impact an oral agent's bioavailability: newly developed adjuvants and well-established adjuvants. The last segment is broken down into many smaller sections. One possible way to address the issues with poorly soluble pharmaceuticals' solubility and availability is to include adjuvants in standard medications.[34] Incorporating excipients into the formulation to facilitate drug dissolving is one method for increasing the solubility and bioavailability of poorly soluble medications. It is also possible to create unique delivery methods that accelerate the pace of breakdown using different strategies. Organic acids (such as citric acid, tartaric acid, and carbonic acid) are examples of pH-modifying agents that may be used to increase the rates at which weakly stable chemicals dissolve. Cyclodextrins are often employed as adjuvants for solubility modification in a variety of settings. These dosage forms comprise solid dispersions and inclusion complexes, two formulation techniques, as well as self-emulsifying delivery systems.[35] One important obstacle A significant portion of the technologies depend on an excipient as a carrier that affects the bioavailability of substances such as extremely absorbent poloxamers, crospovidone, dimethyl of hot water, hydroxypropyl methylcellulose, and crospovidone.[36]

EXCIPIENTS' FUNCTIONS IN BIOAVAILABILITY

Adjuvants that have the potential to impact a drug's oral bioavailability may also have an impact on a drug's bioavailability due to drug-related dose forms and physiological characteristics at the absorption site. For the synthesis of complex molecules, a thorough mechanistic knowledge of the dependency on these interactions is necessary.[37] Chemical excipients may contribute to waste

and emissions related to active ingredients (APIs). Excipients that can be added to chemical formulations to aid in the dissolution of the chemicals or to provide varying amounts of improved water solubility through different methods include cyclodextrins, disintegrants, pH-modifying excipients, and surfactants. Examples that are readily accessible are used to explain the names in detail.[38]

One important obstacle to the creation and management of new pharmaceuticals is the poor water solubility of BCS group II-IV medications. Several methods, including ordered mixing, liquid-solid compaction, micronification, lipid-based formulation, solid dispersion, solvent evaporation, co-precipitation, and solvent deposition, have been used to enhance the water-soluble formulations' bioavailability. Additionally discussed are complexation and steam-assisted granulation. The majority of technologies need an excipient as a carrier, which is important for the bioavailability of crospovidone, dimethyl of hot water, salt, hydroxypropyl methylcellulose, hydroxypropyl cellulose (HPC), and extremely absorbent poloxamer.[39]

PROPER EXCIPIENTS SELECTION

Excipients may work in concert with the active component to provide synergistic effects, but they can also interact with medications and packaging materials; thus, caution should be used when selecting them as an accessory.[40] A crucial stage in the creation of new drugs is selecting the appropriate excipient. Numerous criteria, such as the kind of API, function, target structure, and possible impacts on the product, may be taken into consideration when choosing excipients.

CLASSIFICATIONS OF EXCIPIENTS

Excipients are mostly used in the following applications: disintegration materials, coating materials, emulgents, taste and odor improvers, ointment bases, preservation agents, and consistency improvers. Another major way to classify excipients is according to how well they work inside a dose form. Disintegrants, fillers, binders, lubricants, compression aids, sweeteners, flavors, glidants, colors, preservatives, movie coatings, dispersion advertisers, and printing inks are among the most typical primary excipient activities. Excipients are used in pharmaceuticals, tablets, injections, inhalers, and oral liquids within those categories.[41]

LIST OF EXCIPIENTS

Excipients are essential for improving oral medication bioavailability and overcoming solubility issues.

- Hypromellose acetate succinate
- Cyclodextrin
- Povidone
- Copovidone
- HPC
- Starch

There are a few excipients that can be used to enhance the solubility and bioavailability of poorly water-soluble medications in oral solid dosage forms.

Hydroxypropyl methylcellulose acetate succinate (HPMCAS)

An excipient referred to as HPMCAS has been utilized to address solubility problems with oral medicines that Figure 4 shows structure of hydroxypropy. Although HPMCAS is insoluble in gastric juice, depending on where it is replaced, it starts to expand and leak at a pH over 5**.**HPMCAS has been used to enhance BCS solubility with class II chemicals and to coat tablets with fluids.

Copovidone

An excipient called Copovidone is used as an oral solid to increase medication that is poorly soluble in water in terms of its solubility and bioavailability and Figure 5 illustrates the chemical structure of copovidone. In tablet formulations, the Copovidonea copolymer of vinyl pyrrolidone and vinyl acetate is used as a disintegrant, wet binder, and dry binder. It's also a useful tool for yanking. It has been shown to enhance the dispersion and solubility of weakly soluble medications, including itraconazole, griseofulvin, and fenofibrate. Copovidone and other excipients, such as crospovidone and hydroxypropyl methylcellulose, are used to increase the solubility and bioavailability of medications with poor solubility**.**

HPC

In oral strong dosage documentation, HPC is an excipient that may be added to enhance the tablet's bioavailability and solubility, which are not very water-soluble refer Figure 6 represents the chemical structure of Hydroxypropyl cellulose. HPC is a cellulose ether that dissolves completely in water and polar natural solvents, such as acetone, methanol, ethanol, and isopropyl alcohol.

In pill formulations, HPC serves as a solubilizer, disintegrant, and binder. Itraconazole and caffeine are two examples of medications whose solubility and dissolution rate are improved by HPC. In addition, HPC may be used with other excipients, such as carboxymethylcellulose and polyvinylpyrrolidone, to increase the weakly soluble capsules' bioavailability and solubility.

Starch

Adjuvant starch is administered orally as a solid dose to improve the solubility and bioavailability of the substance in

aqueous solutions the Figure 7 illustrates chemical structure of Starch. One of the most often used adjuvants is starch; its use varies depending on the quantity and mode of addition; it may be employed as a disintegrant, binder, solvent, or partly pre-gelatinized maize starch (Starch 1500, from 80 When used as a secondary two complements, typically in conjunction with microcrystalline cellulose, Starch 1500 has achieved commercial product performance in new vehicle generic and OTC market segments in the majority of countries. It provides low moisture content to provide optimal pellet hardness and low friability, which are the final round of benefits. Crucial for packaging and film coatings; additionally, starch may be combined with other excipients, including porous starch, to improve the bioavailability and dissolution of low-soluble medicines**.**

CONCLUSION

Poorly soluble drugs may have their solubility and bioavailability increased using a variety of techniques and adjuvants. Physical alterations include lipid formation, solid dispersion, amorphous formulation, cocrystal formation, and medication size decrease. Drug stability and bioavailability may also be improved by the use of excipients like lipids and surfactants. Another excipient that may be used to improve the solubility of poorly-soluble medications is cyclodextrin. The drug's physicochemical characteristics and the preferred administration method will dictate route selection. Predicting fetal physiological results and ensuring consistent bioavailability are critical during medication development. Surfactants can self-assemble into a variety of forms, including liposomes and micelles, and stabilize emulsions. All things considered, using these techniques and excipients may be a useful tactic to deal with solubility issues and enhance the bioavailability of oral medications.

REFERENCES

1. Schneider G. Prediction of drug-like properties. In: Madame Curie Bioscience Database. United States: Landes Bioscience; 2013.
2. Stegemann S, Leveiller F, Franchi D, De Jong H, Lindén H. When poor solubility becomes an issue: From early stage to proof of concept. Eur J Pharm Sci 2007;31:249-61.
3. Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 2002;45:2615-23.
4. Vallianatou T, Giaginis C, Tsantili-Kakoulidou A. The impact of physicochemical and molecular properties in drug design: Navigation in the "drug-like" chemical space. In: GeNeDis 2014: Neurodegeneration. Springer International Publishing; 2015. p. 187-94.
5. Arnott JA, Planey SL. The influence of lipophilicity in drug discovery and design. Expert Opin Drug Discov 2012;7:863-75.
6. Morak-Młodawska B, Jeleń M, Martula E, Korlacki R. Study of lipophilicity and ADME properties of 1,9-diazaphenothiazines with anticancer action. Int J Mol Sci 2023;24:6970.
7. Van Eyk AD, Van der Bijl P, Moll LM. Physicochemical characteristics of molecules and their diffusion across human vaginal mucosa. Eur J Inflamm 2008;6:65-71.
8. Thenge R, Adhao V, Mehetre G, Chopade N, Chinchole P, Popat R, *et al*. Modification of physicochemical properties of active pharmaceutical ingredient by pharmaceutical Co-crystals. Drug formulation design. London: IntechOpen; 2023.
9. Yadav AV, Shete AS, Dabke AP, Kulkarni PV, Sakhare SS. Co-crystals: A novel approach to modify physicochemical properties of active pharmaceutical ingredients. Indian J Pharm Sci 2009;71:359-70.
10. Bongioanni A, Bueno MS, Mezzano BA, Longhi MR, Garnero C. Pharmaceutical crystals: Development, optimization, characterization and biopharmaceutical aspects. In: Crystal Growth-Technologies and Applications. London: IntechOpen; 2022.
11. Schultheiss N, Newman A. Pharmaceutical cocrystals and their physicochemical properties. Cryst Growth Des 2009;9:2950-67.
12. Ferguson LN. Hydrogen bonding and physical properties of substances. J Chem Educ 1956;33:267.
13. Caron G, Kihlberg J, Ermondi G. Intramolecular hydrogen bonding: An opportunity for improved design in medicinal chemistry. Med Res Rev 2019;39:1707-29.
14. Ai F, Wang J, Li Y, Ma Y. Effect of drug particle size on complexation, physicochemical properties and dissolution of cyclodextrin inclusion complexes. Indian J Pharma Sci 2017;79:131-8.
15. Kovvasu SP. Cyclodextrins and their application in enhancing the solubility, dissolution rate and bioavailability. Innoriginal: Int J Sci 2018:25-34.
16. Fahr A, Liu X. Drug delivery strategies for poorly water-soluble drugs. Expert Opin Drug Deliv 2007;4:403-16.
17. Alqahtani MS, Kazi M, Alsenaidy MA, Ahmad MZ. Advances in oral drug delivery. Front Pharmacol 2021;12:618411.
18. Salunke S, O'Brien F, Cheng Thiam Tan D, Harris D, Math MC, Ariën T, *et al*. Oral drug delivery strategies for development of poorly water soluble drugs in paediatric patient population. Adv Drug Deliv Rev 2022;190:114507.
19. Jornada DH, dos Santos Fernandes GF, Chiba DE, De Melo TR, Dos Santos JL, Chung MC. The prodrug approach: A successful tool for improving drug solubility. Molecules 2015;21:42.
20. Karaman R. Prodrugs design based on inter-and intramolecular chemical processes. Chem Biol Drug Des 2013;82:643-68.
21. Sareen S, Mathew G, Joseph L. Improvement in solubility of poor water-soluble drugs by solid dispersion. Int J

Pharm Investig 2012;2:12-7.
22. Sun J, Wang F, Sui Y, She Z, Zhai W, Wang C, *et al*. Effect of particle size on solubility, dissolution rate, and oral bioavailability: Evaluation using coenzyme Q10 as naked nanocrystals. Int J Nanomedicine 2012;7:5733.
23. Khadka P, Ro J, Kim H, Kim I, Kim JT, Kim H, *et al*. Pharmaceutical particle technologies: An approach to improve drug solubility, dissolution and bioavailability. Asian J Pharm Sci 2014;9:304-16.
24. Kumari L, Choudhari Y, Patel P, Gupta GD, Singh D, Rosenholm JM, *et al*. Advancement in solubilization approaches: A step towards bioavailability enhancement of poorly soluble drugs. Life (Basel) 2023;13:1099.
25. Bhalani DV, Nutan B, Kumar A, Singh Chandel AK. Bioavailability enhancement techniques for poorly aqueous soluble drugs and therapeutics. Biomedicines 2022;10:2055.
26. Yeh MK, Chang LC, Chiou AH. Improving tenoxicam solubility and bioavailability by cosolvent system. AAPS PharmSciTech 2009;10:166-71.
27. Gupta S, Kesarla R, Omri A. Formulation strategies to improve the bioavailability of poorly absorbed drugs with special emphasis on self-emulsifying systems. ISRN Pharm 2013;2013:848043.
28. Mohite P, Singh S, Pawar A, Sangale A, Prajapati BG. Lipid-based oral formulation in capsules to improve the delivery of poorly water-soluble drugs. Front Drug Deliv 2023;3:1232012.
29. Fatouros DG, Karpf DM, Nielsen FS, Mullertz A. Clinical studies with oral lipid based formulations of poorly soluble compounds. Ther Clin Risk Manag 2007;3:591-604.
30. Müllertz A, Ogbonna A, Ren S, Rades T. New perspectives on lipid and surfactant based drug delivery systems for oral delivery of poorly soluble drugs. J Pharm Pharmacol 2010;62:1622-36.
31. Conceição J, Adeoye O, Cabral-Marques HM, Lobo JM. Cyclodextrins as excipients in tablet formulations. Drug Discov Today 2018;23:1274-84.
32. Tiwari G, Tiwari R, Rai AK. Cyclodextrins in delivery systems: Applications. J Pharm Bioallied Sci 2010;2:72-9.
33. Ramos-Martínez B, Dávila-Pousa C, Merino-Bohórquez V, García-Palomo M, Flox-Benítez MªP. Use of cyclodextrins as excipients in pharmaceutical products: Why not in extemporaneous preparations? Farm Hosp 2022;46:31-9.
34. Zhang L, Chen Q, Hou G, Zhao W, Hou Y. Hydroxyl-substituted double Schiff-base condensed 4-piperidone/cyclohexanones as potential anticancer agents with biological evaluation. J Enzyme Inhib Med Chem 2019;34:264-71.
35. Schieder S, Nemecek E, Schuh R, Kolb A, Windhager R, Willegger M. Radiographic sagittal tibio-talar offset in ankle arthrodesis-accuracy and reliability of measurements. J Clin Med 2020;9:801.
36. Choquesillo-Lazarte D, Domínguez-Martín A. Multicomponent pharmaceutical solids. Crystals 2023;13:570.
37. Panakanti R, Narang AS. Impact of excipient interactions on drug bioavailability from solid dosage forms. Excip Appl Formul Design Drug Deliv 2015;15:273-310.
38. Van der Merwe J, Steenekamp J, Steyn D, Hamman J. The role of functional excipients in solid oral dosage forms to overcome poor drug dissolution and bioavailability. Pharmaceutics 2020;12:393.
39. Vadlamudi MK, Dhanaraj S. Significance of excipients to enhance the bioavailability of poorly water-soluble drugs in oral solid dosage forms: A review. IOP Conf Ser: Mater Sci Eng 2017;263:022023.
40. Rayaprolu BM, Strawser JJ, Anyarambhatla G. Excipients in parenteral formulations: Selection considerations and effective utilization with small molecules and biologics. Drug Dev Ind Pharm 2018;44:1565-71.
41. Bachmaier RD, Monschke M, Faber T, Krome AK, Pellequer Y, Stoyanov E, *et al*. *In vitro* and *in vivo* assessment of hydroxypropyl cellulose as functional additive for enabling formulations containing itraconazole. Int J Pharm X 2021;3:100076.

Source of Support: Nil. **Conflicts of Interest:** None declared.